Wire · regulatory
FDA approves Lilly's Inluriyo-Verzenio combination for advanced breast cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
The FDA has granted full approval for Eli Lilly's Inluriyo in combination with Verzenio for adults with advanced breast cancer carrying ESR1 mutations, based on Phase 3 EMBER-3 trial results showing doubled median progression-free survival compared to Inluriyo alone.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You can now offer a proven oral combination therapy for ESR1-mutated breast cancer that extends patient progression-free survival without adding complex monitoring. This clears a path to replace older treatments with a safer, more effective regimen proven in late-stage trials.
◆ Coverage
5 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics